share_log

藥明生物：翌日披露報表

WUXI BIO: Next Day Disclosure Returns

Hong Kong Stock Exchange ·  Apr 16 20:21
Summary by Futu AI
药明生物技术有限公司於2024年4月16日提交了最新的股份變動及股份購回報告。報告顯示，公司在2023年12月7日至2024年4月16日期間，進行了多次股份購回但未註銷股份。其中，2024年4月16日當天，公司於香港聯合交易所購回了1,510,000股普通股，每股價格介於HKD 12.9至HKD 13.42之間，總計購回金額達到HKD 19,893,230。自普通決議案通過以來，公司在香港聯合交易所購回的股份總數達到91,587,000股，佔已發行股份的2.15579%。此外，公司於2024年4月12日根據股份期權計劃行使期權發行了4,000股新股，發行價為每股HKD 2.04，較上一個營業日的收市價HKD 14.1折讓85.53%。截至2024年4月16日，药明生物的結存已發行股份為4,259,139,569股。
药明生物技术有限公司於2024年4月16日提交了最新的股份變動及股份購回報告。報告顯示，公司在2023年12月7日至2024年4月16日期間，進行了多次股份購回但未註銷股份。其中，2024年4月16日當天，公司於香港聯合交易所購回了1,510,000股普通股，每股價格介於HKD 12.9至HKD 13.42之間，總計購回金額達到HKD 19,893,230。自普通決議案通過以來，公司在香港聯合交易所購回的股份總數達到91,587,000股，佔已發行股份的2.15579%。此外，公司於2024年4月12日根據股份期權計劃行使期權發行了4,000股新股，發行價為每股HKD 2.04，較上一個營業日的收市價HKD 14.1折讓85.53%。截至2024年4月16日，药明生物的結存已發行股份為4,259,139,569股。
Pharma Ming Biotechnology Co., Ltd. filed its latest stock changes and share repurchase report on April 16, 2024. The report shows that the company made several share repurchases but did not write off shares between December 7, 2023 and April 16, 2024. Of these, on 16 April 2024, the Company repurchased 1,510,000 shares of ordinary shares on the Hong Kong Stock Exchange at a price of between HKD 12.9 and HKD 13.42 for a total repurchase amount of HKD 19,893,230. Since the adoption of the Ordinary Resolution, the total number of shares repurchased by the Company on the Hong Kong Stock Exchange has reached 91,587,000 shares, representing 2.15579% of the issued shares. In addition, the Company issued 4,000 new shares under the Share Option Scheme on 12 April 2024 at a price of HKD 2.04 per share, representing an increase of HKD 14.1% from the previous business day's closing price of HKD 85.53%. As of April 16, 2024, Pharmaceuticals had issued shares of 4,259,139,569 shares.
Pharma Ming Biotechnology Co., Ltd. filed its latest stock changes and share repurchase report on April 16, 2024. The report shows that the company made several share repurchases but did not write off shares between December 7, 2023 and April 16, 2024. Of these, on 16 April 2024, the Company repurchased 1,510,000 shares of ordinary shares on the Hong Kong Stock Exchange at a price of between HKD 12.9 and HKD 13.42 for a total repurchase amount of HKD 19,893,230. Since the adoption of the Ordinary Resolution, the total number of shares repurchased by the Company on the Hong Kong Stock Exchange has reached 91,587,000 shares, representing 2.15579% of the issued shares. In addition, the Company issued 4,000 new shares under the Share Option Scheme on 12 April 2024 at a price of HKD 2.04 per share, representing an increase of HKD 14.1% from the previous business day's closing price of HKD 85.53%. As of April 16, 2024, Pharmaceuticals had issued shares of 4,259,139,569 shares.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.